
New patient- and caregiver-reported outcomes across 3 phase 3 trials demonstrated improved itch and reduced impact of AD on sleep in patients 2 years and older.

New patient- and caregiver-reported outcomes across 3 phase 3 trials demonstrated improved itch and reduced impact of AD on sleep in patients 2 years and older.

Updated 2025 CPR guidelines from the AAP and AHA include revisions to pediatric and neonatal resuscitation, reflecting new evidence and a unified chain of survival.

In this Q&A, Abby Nerlinger, MD, breaks down how pediatricians can provide detailed care for children with military connections, based on a session presented at the 2025 AAP National Conference & Exhibition.

In this brief clip, Lori Handy, MD, MSCE, of CHOP, explains the evolving dynamic of trust between patients, parents, and health care.


Lori Handy, MD, MSCE, discussed how clinicians can strengthen vaccine communication by engaging openly and partnering with trusted community messengers.

Nicholas P. Marshall, MD, FAAP, discussed how generative AI can help streamline infectious disease workflows and enhance evidence-based care at IDWeek 2025 in Atlanta.

Yohei Doi, MD, IDWeek chair, Infectious Diseases Society of America, provides some insights on the happenings at this year’s event from Atlanta, Georgia.

Children born preterm face significantly reduced odds of completing high school and university compared with full-term peers.

* Generic lenacapavir could be produced for $25 per person per year at scale, according to an analysis presented at IDWeek 2025 in Atlanta.

Unintentional marijuana ingestions in children under 5 rose over 1,000% in 7 years, with edibles and pandemic-related factors fueling the trend.

Combined or individual use of maternal RSVpreF and infant nirsevimab achieved high antibody levels without safety concerns, supporting current RSV prevention strategies.

A study of 3,438 toddlers found slightly lower emotional and behavioral problems among children assessed during the COVID-19 pandemic.

Tezepelumab received FDA approval for CRSwNP in patients 12 years and older, supported by strong phase 3 data.

At CNS 2025, Kathryn Xixis, MD, highlighted the growing adoption of EPAs and outcomes-based learning in pediatric neurology.

Indication expansions include hidradenitis suppurativa for patients 12 years and up, as well as for patients with uveitis aged 2 years and older.

In our second interview with Peace Madueme, MD, he explains the types of conditions that frequently appear on ECGs, which are aiding routine sports physicals in youth athletes in Florida.

A pediatrician warns of the resurgence of vaccine-preventable diseases, urging awareness of their devastating impacts on children's health.

IDWeek 2025 heads to Atlanta October 19–22 with cutting-edge sessions on AMR, AI, vaccines, HIV, pediatrics, and global health challenges.

IDSA’s new GAS pharyngitis guidance emphasizes selective testing using clinical scoring to reduce overtreatment and antibiotic misuse.

At the 2025 CNS Annual Meeting, Craig Press, MD, PhD, discussed challenges in achieving equitable access to diagnostics and expertise in pediatric neurocritical care.

Craig Press, MD, PhD, discussed the evolution of pediatric neurocritical care toward individualized care at the 2025 Child Neurology Society meeting.

Integrating health care and behavioral science transforms experiences for neurodivergent children, reducing anxiety and fostering confidence during medical procedures.

In a recent trial, 11 of 12 children treated with DB-OTO demonstrated meaningful hearing gains.

FDA accepts MannKind’s sBLA for Afrezza in children and adolescents with diabetes.

This issue has a number of outstanding must-read articles related to pediatric vaccines.

Explore effective techniques for gathering psychosocial histories from adolescents using the HEADS FIRST Checklist to enhance mental health interventions.

Can you guess the diagnosis?

Discover the benefits of shea butter-based emollients in diapers, offering effective protection against diaper rash and skin irritation for babies.

Tapering adalimumab in inflammatory arthritis reduces flare rates and enhances recovery compared to abrupt discontinuation.